Download Files:
CFT8634
$820 – $4,150
Products Details
Product Description
– CFT8634 is an oral activity degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors[1][2].
Web ID
– HY-145925B
Storage Temperature
– 4°C (Powder, protect from light, stored under nitrogen)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C37H45F3N6O5
References
– [1]Nasveschuk CG, et, al. Compounds for targeted degradation of brd9. WO2021178920A1.|[2]Brian A, et.al. A Phase 1/2 Study of CFT8634, a Novel Bifunctional Degradation Activating Compound (BIDACmDegrader Of BRD9, in Synovial Sarcoma and SMARCB1-null Tumors.
CAS Number
– 2704617-96-7
Molecular Weight
– 710.79
Compound Purity
– 98.60
SMILES
– CC(C(C1=CC(OC)=C(C(OC)=C1)CN2CC(F)([C@@H](N3CCN(C4=C(C=C(C=C4)N[C@@H]5C(NC(CC5)=O)=O)F)CC3)CC2)F)=CN6C)=C(C)C6=O
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Epigenetic Reader Domain
Pathway
– Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
